• *** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know
NephroGenex, Inc. is a pharmaceutical company, which focuses on the development of therapeutics to treat kidney disease, an area of significant unmet medical need. It is developing Pyridorin, a small molecule drug that is acting inhibitor of the pathogenic oxidative chemistries which are elevated in diabetic patients. The company was founded by Billy G. Hudson, J. Wesley Fox Ahmann and Tryggvason Karl on May 25, 2004 and is headquartered in Raleigh, NC.
| Market Cap | 1.813 Million | Shares Outstanding | 12.95 Million | Avg 30-day Volume | 647.672 Thousand |
| P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | -2.29 |
| Price to Revenue | 0.0 | Debt to Equity | 0.5835 | EBITDA | -22.274 Million |
| Price to Book Value | 1.8591 | Operating Margin | 0.0 | Enterprise Value | 5.469 Million |
| Current Ratio | 2.973 | EPS Growth | -0.065 | Quick Ratio | 2.843 |
| 1 Yr BETA | 0.6859 | 52-week High/Low | 0.0 / | Profit Margin | 0.0 |
| Operating Cash Flow Growth | -43.9727 | Altman Z-Score | -6.2686 | Free Cash Flow to Firm | -14.131 Million |
Please sign in first
none
none
none
| Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
|---|---|---|---|---|
|
76,045 | 2015-12-09 | 0 | |
|
LEGAULT PIERRE CHIEF EXECUTIVE OFFICER |
|
659,430 | 2015-11-10 | 0 |
|
HAMILL JOHN CHIEF FINANCIAL OFFICER |
|
136,381 | 2015-11-10 | 0 |
|
PATEL JAIKRISHNA CHIEF MEDICAL OFFICER |
|
97,306 | 2015-11-10 | 0 |
|
FOX J. WESLEY PRES. & CHIEF SCI. OFFICER |
|
No longer subject to file | 2015-09-01 | 0 |
|
0 | 2015-04-30 | 0 | |
|
0 | 2015-04-30 | 0 | |
|
PETERSON BOB VP OF PROD. DEV. & REG. AFF'S. |
|
No longer subject to file | 2015-04-30 | 0 |
|
0 | 2015-04-30 | 0 | |
|
0 | 2015-04-30 | 0 | |
|
1,052,966 | 2015-01-02 | 0 |
| Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No current insider transactions | ||||||||||||||||
* -
| Code | Definition |
|---|---|
| A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
| C | Conversion of derivative security |
| D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
| E | Expiration of short derivative position |
| F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
| G | Bona fide gift |
| H | Expiration (or cancellation) of long derivative position with value received |
| I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
| J | Other acquisition or disposition |
| L | Small acquisition under Rule 16a-6 |
| M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
| O | Exercise of out-of-the-money derivative security |
| P | Open market or private purchase of non-derivative or derivative security |
| S | Open market or private sale of non-derivative or derivative security |
| U | Disposition pursuant to a tender of shares in a change of control transaction |
| W | Acquisition or disposition by will or the laws of descent and distribution |
| X | Exercise of in-the-money or at-the-money derivative security |
| Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
| Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
|---|
| Holder | Issuer | Net Short Position | Position Date | Origin |
|---|
